Glycoprotein IIb/IIIa inhibitors in clinical practice;Inibidores da glicoproteína IIb/IIIa na prática clínica

Arquivos Brasileiros de Cardiologia

Volumn 92, Issue 1, 2009, Pages 65-73

  Maia, Felipe ^a   De Sá, Francisco Carleal Feijó ^a   Feres, Fausto ^a,b  

^a INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^b NONE   (Brazil)

Author keywords

Glycoprotein IIb IIIa receptor inhibitors; Percutaneous coronary intervention; Platelet aggregation

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RETEPLASE; THIENOPYRIDINE DERIVATIVE; TIROFIBAN;

ACUTE CORONARY SYNDROME; BLEEDING; BRAIN HEMORRHAGE; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG COST; DRUG WITHDRAWAL; ELECTIVE SURGERY; HEALTH CARE COST; HUMAN; INCIDENCE; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVIEW; SINGLE DRUG DOSE; ST SEGMENT ELEVATION;

EID: 60949107061     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2009000100011     Document Type: Review

References (45)

1. Williams D, Holubkov R, Yeh W, Bourassa MG, Al-Bassam M, Block PE, et al. Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung and Blood Institute Registry. Circulation. 2000; 102: 2945-51.
2. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Trial Investigation. N Engl J Med. 1994; 330: 956-61.
3. Platelet glycoprotein iib/iiia receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med. 1997; 336: 1689-96.
4. Randomized placebo-controlled and Balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein. IIb/IIIa blockade. EPISTENT Investigators. Lancet. 1998; 352: 87-92.
5. Mehta SR, Ysuf S, Peters RJ. The clopidogrel in unstable angina to prevent recurrent ischemic events trial investigators: effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494-502.
6. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006; 355: 2203-16.
7. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006; 354: 1464-76.
8. O'Shea JC, Madan M, Cantor WJ, Pacchiana CM, Greenberg S, Joseph DM, et al. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen eptifibatide in percutaneous coronary intervention. Am Heart J. 2000; 140: 834-9.
9. Gibson CM, Goel M, Cohen DJ, Piana RN, Deckeslbaum LI, Harris KE, et al. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. J Am Coll Cardiol. 1998; 32: 28-34.
10. Kandzari DE, Berger PB, Kastrati A, for the ISAR-REACT Study Investigators. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol. 2004; 44: 2133-6.
11. Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Centro Nacional de Intervenções Cardiovasculares. CENIC. Estatística Ano 2005. (on line). [Acesso em: 2008 jan 05]. Disponível em: http://www.sbhci.org.br.
12. Kinh SB3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guideline. J Am Coll Cardiol. 2008; 51 (2): 172-209.
13. Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, et al. European Society of Cardiology: Task Force for Percutaneous Coronary Intervention of the European Society of Cardiology. Guidelines for percutaneous coronary intervention. Eur Heart J. 2005; 26: 804-47.
14. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol. 2000; 35: 1535-42.
15. The PRISM-PLUS investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med. 1998; 338: 1488-97.
16. Moliterno DJ, for The PARAGON B International Steering Committee. Patient specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. Am Heart J. 2000; 139: 563-6.
17. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndrome. The PURSUIT Trial investigators. Platelets Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Intergrilin Therapy. N Engl J Med. 1998; 339: 436-43.
18. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006; 295 (13): 1531-8.
19. Marmur JD, Mitre CA, Barnathan ES, Cavosoglu E. Benefit of bolus-only glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC trial). Am Heart J. 2006; 152: 876-81.
20. Fischell TA, Attia TA, Rane SG. High dose, single-bolus eptifibatide is effective in preventing non-Q wave myocardial infarction with minimal bleeding complications in elective coronary stenting (abstract). Am J Cardiol. 2005; 96 (Suppl 7A): 153H.
21. Gilchrist IC, O'Shea JC, Kosoglou T, Jennings LK, Lorenz TJ, Kitt MM, et al. Pharmacodynamics and pharmacokinetics of higher-dose double-bolus eptifibitide in percutaneous coronary intervention. Circulation. 2001; 104: 406-11.
22. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001; 344: 1888-94.
23. Valgimigli M, Peroco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, et al. The additive value of tirofibam administered with the high-dose bolus in the prevention of ischaemic complications during high-risk coronary angioplasty. J Am Coll Cardiol. 2004; 44: 14-9.
24. Dawson CB, Mukherjee D, Valgimigli M, Charnigo R, Walters DL, Danzi GB, et al. Meta-analysis of trials with higher dose single-bolus tirofiban versus abciximab in patients undergoing percutaneous coronary interventions. (abstract). Circulation. 2006; 114: II-647.
25. Simoons ML, GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomized trial. Lancet. 2001; 357: 1915-24.
26. Stone GW, Bertrand ME, Moses JW, Ohman M, Lincoff AM, Ware JH, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA. 2007; 297: 591-602.
27. Wijpkema JS, Jessurn GA, Van Boven AJ, Versteeg DI, Haustvast RW, Tio RA. Clinical impact of abciximab on long-term outcome after complex coronary angioplasty. Catheter Cardiovasc Interv. 2003; 60: 339-43.
28. Kandzari DE, Hasselbla V, Tcheng JE, Stone GW, Califf RM, Kastrati A, et al. Improved clinical outcome with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J. 2004; 147: 457-62.
29. Montalescot G, Borentaim M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2004; 292 (3): 362-6.
30. Maioli M, Bellandi F, Leoncini M, Toso A, Dabizzi R. Randomized early versus late Abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). J Am Coll Cardiol. 2007; 49: 1517-24.
31. Srinivas VS, Skeif B, Negassa A, Bang J, Shagra H, Monrad E. Effectiveness of glycoprotein IIb/IIIa inhibitor use during primary coronary angioplasty: results of propensity analysis using the New York State Percutaneous Coronary Intervention Reporting System. Am J Cardiol. 2007; 99: 482-5.
32. Al-Mallah MH, Sinno MC. The efficacy and safety of thrombolytic facilitated PCI for ST-elevation myocardial infarction? A meta analysis of randomized clinical trials (abstract). Circulation. 2005; 112 (17 Suppl II): II-620.
33. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet. 2006; 367: 579-88.
34. Topol EJ, GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001; 357: 1905-14.
35. Ellis SG, Tendera M, Topol EJ, et al. Facilitated PCI in Patients With ST-Elevation Myocardial Infarction - FINESSE Investigators. N Engl J Med 2008; 358: 2205-17.
36. Laskey WK, Selzer F, Vlachos HA, Johnston J, Jacobs A, King SB 3rd, et al. Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol. 2002; 90: 1062-7.
37. Marso SP, Lincoff AM, Ellis SG, Bhatt DL, Tanguay JF, Kleiman NS, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation. 1999; 100: 2477-84.
38. Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, et al. Randomized clinical trial of abciximab in diabetic patients undergoing percutaneous coronary interventions after treatment with a high loading dose of clopidogrel for the intracoronary stenting and antithrombotic regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET). Circulation. 2004; 110: 3627-35.
39. Chaves AJ, Sousa AG, Mattos LA, Abizaid A, Staico R, Feres F, et al. Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab: results of the Diabetes Abciximab stent Evaluation (DANTE) randomized trial. Circulation. 2004; 109: 861-6.
40. Montalescot G, Antoniucci D, Kastrati A, Neumann FJ, Borentain M, Migliorini A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J. 2007; 28 (4): 443-9.
41. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment coronary syndromes. Circulation. 2001; 104: 2767-71.
42. Lincoff AM, Bittl JA, Harrington R, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003; 289: 853-63.
43. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007; 369: 907-19.
44. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the managment of patients with unstable angina / non ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007; 50 (7): e1-e157.
45. Yussuf S, Mheta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006; 295 (13): 1519-30.